Related Experiment Video
Updated: Aug 8, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Cells producing low-molecular-weight antibody to Escherichia coli lipopolysaccharide
CD-1 mice immunized with sheep red blood cells (SRBC) or Escherichia coli lipopolysaccharide (LPS), developed splenic plaque-forming cells (PFC) producing low-molecular-weight antibody; these cells were detected by means of purified rabbit antisera to mouse gamma(1), gamma(2a), and gamma(2b) immunoglobulins. In contrast to SRBC, the primary gamma(1) response to LPS was absent and gamma(2a) and gamma(2b) PFC were detected irregularly. Both immunogens elicited a secondary cellular response in all three subclasses without a corresponding increase in "direct" or gamma(M) PFC. An increase in serum bactericidal antibody following a second injection of LPS was not parallelled by an increase in splenic gamma(M) PFC; it might therefore involve the synthesis of gamma(2) complement-fixing antibody.
CD-1 mice immunized with sheep red blood cells (SRBC) or Escherichia coli lipopolysaccharide (LPS), developed splenic plaque-forming cells (PFC) producing low-molecular-weight antibody; these cells were detected by means of purified rabbit antisera to mouse gamma(1), gamma(2a), and gamma(2b) immunoglobulins. In contrast to SRBC, the primary gamma(1) response to LPS was absent and gamma(2a) and gamma(2b) PFC were detected irregularly. Both immunogens elicited a secondary cellular response in all three subclasses without a corresponding increase in "direct" or gamma(M) PFC. An increase in serum bactericidal antibody following a second injection of LPS was not parallelled by an increase in splenic gamma(M) PFC; it might therefore involve the synthesis of gamma(2) complement-fixing antibody.
More Related Videos
08:46Cell-Free Production of Proteoliposomes for Functional Analysis and Antibody Development Targeting Membrane Proteins
Published on: September 22, 2020
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022